Mark Lundeen

Mark Lundeen

Auto-generated profile, based on publicly available information

Mark Lundeen

Sanford Orthopedics and Sports Medicine Fargo, Fargo, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
JFJohn P. Furia
John P. Furia
MLMark A. Lundeen
Mark A. Lundeen
JHJason L. Hurd
Jason L. Hurd
DPDavid A. Pearce
David A. Pearce
CAChristopher Alt
Christopher Alt
Nicola MaffulliNicola Maffulli
Nicola Maffulli
Background: Recently, the management of musculoskeletal disorders with the patients' own stem cells, isolated from the walls of small blood vessels, which can be found in great numbers in the adipose tissue, has received considerable attention. On the other hand, there are still misconceptions about these adipose-derived regenerative cells (ADRCs) that contain vascular-associated pluripotent stem cells (vaPS cells) in regenerative medicine. Methods: Based on our previous publications on this topic, we have developed a concept to describe the significance of the ADRCs/vaPS cells in the field of orthobiologics as briefly as possible and at the same time as precisely as possible. Results: The ADRCs/vaPS cells belong to the group of orthobiologics that are based on autologous cells. Because the latter can both stimulate a patient’s body's localized self-healing power and provide new cells that can integrate into the host tissue during the healing response when the localized self-healing power is exhausted, this group of orthobiologics appears more advantageous than cell-free orthobiologics and orthobiologics that are based on allogeneic cells. Within the group of orthobiologics that are based on autologous cells, enzymatically isolated, uncultured ADRCs/vaPS cells have several advantages over non-enzymatically isolated cells/microfragmented fat as well as over uncultured bone marrow aspirate concentrate and cultured cells (adipose-derived stem cells, bone marrow-derived mesenchymal stem cells). Conclusions: The use of ADRCs/vaPS cells can be seamlessly integrated into modern orthopedic treatment concepts, which can be understood as the optimization of a process which—albeit less efficiently—also takes place physiologically. Accordingly, this new safe and effective type of treatment is attractive in terms of holistic thinking and personalized medicine.

7 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MLMark Lundeen
Mark Lundeen
JHJason L. Hurd
Jason L. Hurd
MHMatthew Hayes
Matthew Hayes
MHMeredith Hayes
Meredith Hayes
TFTiffany R. Facile
Tiffany R. Facile
DPDavid A. Pearce
David A. Pearce
Symptomatic, partial-thickness rotator cuff tears (sPTRCT) are problematic. This study tested the hypothesis that management of sPTRCT with injection of fresh, uncultured, unmodified, autologous, adipose-derived regenerative cells (UA-ADRCs) is safe and more effective than injection of corticosteroid even in the long run. To this end, subjects who had completed a former randomized controlled trial were enrolled in the present study. At baseline these subjects had not responded to physical therapy treatments for at least 6 weeks, and were randomly assigned to receive respectively a single injection of UA-ADRCs (n = 11) or a single injection of methylprednisolone (n = 5). Efficacy was assessed using the ASES Total score, pain visual analogue scale (VAS), RAND Short Form-36 Health Survey and range of motion at 33.2 ± 1.0 (mean ± SD) and 40.6 ± 1.9 months post-treatment. Proton density, fat-saturated, T2-weighted MRI of the index shoulder was performed at both study visits. There were no greater risks connected with injection of UA-ADRCs than those connected with injection of corticosteroid. The subjects in the UA-ADRCs group showed statistically significantly higher mean ASES Total scores than the subjects in the corticosteroid group. The MRI scans at 6 months post-treatment allowed to “watch the UA-ADRCs at work”.

14 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MLMark Lundeen
Mark Lundeen
JHJason L. Hurd
Jason L. Hurd
MHMatthew Hayes
Matthew Hayes
MHMeredith Hayes
Meredith Hayes
TFTiffany R. Facile
Tiffany R. Facile
DPDavid A. Pearce
David A. Pearce
Objective Symptomatic, partial-thickness rotator cuff tears (sPTRCT) are problematic. Management of sPTRCT with fresh, uncultured, unmodified, autologous, adipose-derived regenerative cells (UA-ADRCs) isolated from lipoaspirate at the point of care is safe and leads to improved shoulder function without adverse effects. This study tested the hypothesis that managemen t of sPTRCT with injection of UA-ADRCs is safe and more effective than injection of corticosteroid even in the long run. Methods Subjects who had completed a former randomized controlled trial were enrolled in the present study. At baseline these subjects had not responded to physical therapy treatments for at least six weeks, and were randomly assigned to receive respectively a single injection of an average 11.4 × 106 UA-ADRCs (n = 11) or a single injection of 80 mg of methylprednisolone (n = 5). Safety was assessed by rigorously documenting and evaluating treatment emergent adverse events. Efficacy was assessed using the ASES Total score, pain visual analogue scale (VAS) and RAND Short Form-36 Health Survey at 33.2 ± 1.0 (mean ± standard deviation) and 40.6 ± 1.9 months post-treatment. Proton density, fat-saturated, T2-weighted (PD FS T2), magnetic resonance imaging (MRI) of the index shoulder was performed at both study visits. Results There were no greater risks connected with injection of UA-ADRCs than those connected with injection of corticosteroid. The subjects in the UA-ADRCs group showed statistically significantly higher mean ASES Total scores than the subjects in the corticosteroid group. Treatment outcome could not be assessed using measurements of tear volume on MRI scans. On the other hand, PD FS T2 MRI scans at six months post-treatment allowed to "watch the UA-ADRCs at work". There was no relationship between treatment outcome and baseline data, including those data characterizing UA-ADRCs that can be collected with a clinical test. Conclusions The present study further supports treatment of sPTRCT with injection of UA-ADRCs. Trial registration Clinicaltrials.gov NCT04077190 (September 4, 2019).